上海羽冠生物技术

FeatherCrown Biotech is a synthetic biology company headquartered in Shanghai, China, focused on the development of innovative attenuated vaccines for infectious diseases. The company leverages its proprietary C-PRO (Codon Pair de-Optimization) platform to design vaccine candidates that trigger robust mucosal and systemic immune responses. Its lead candidate, FC001, is an intranasal live-attenuated COVID-19 vaccine that has entered clinical trials. FeatherCrown aims to address global health challenges by creating safer and more effective vaccines using advanced genomic recoding technologies. The firm has secured significant funding from leading investors such as Matrix Partners China and Qiming Venture Partners to advance its pipeline.